One Nucleus Strikes Collaboration Deal with Science Exchange To Support Members’ Outsourced R&D Strategies
Science Exchange, the leading marketplace for outsourced R&D™ , announced today that it has become a Corporate Partner of One Nucleus, the membership organization for life science and healthcare companies. This exclusive partnership will give One Nucleus members immediate access to thousands of CROs, CMOs, academic institutes, core labs and a global community of scientists from the world’s top R&D organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180912006008/en/
Based in Cambridge, England, One Nucleus supports institutions, companies, and individuals in its region by connecting them to a vast network of UK-wide and global resources. By providing this connectivity, One Nucleus seeks to maximize the productivity of its members.
"One Nucleus shares our mission of enabling scientific breakthroughs through human connections," said Elizabeth Iorns, Ph.D., founder and CEO of Science Exchange. “We look forward to working together with One Nucleus to help its members gain access to external innovations and take their science on the fastest path to breakthroughs.”
“Science Exchange is the primary outsourcing channel for most of the top R&D organizations,” stated Tony Jones, CEO of One Nucleus. “We’re excited about this partnership and how it will enable our members to evaluate their outsourcing and procurement strategies whilst connecting with Science Exchange’s partners and providers.”
About Science Exchange
Science Exchange is the world's Leading Marketplace for Outsourced R&D™ , providing large R&D organizations with the fastest path from discovery through development and commercialization. Science Exchange includes an efficient source-to-secure platform for ordering 6,000+ services from a network of more than 2,500 qualified outsourced research providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com . Follow the company on Twitter @ScienceExchange .
About One Nucleus
Established in 1997, One Nucleus is an award-winning, not-for-profit Life Sciences & Healthcare membership organisation centred on the Greater London-Cambridge-East of England corridor. Headquartered in Cambridge, at the heart of Europe’s largest Life Sciences & Healthcare cluster, we support those institutions, companies and individuals undertaking activity in or with the above region.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
FL-MLB22.9.2018 00:15 | pressemeddelelse
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)
NY-BCW/PALLADINO21.9.2018 19:45 | pressemeddelelse
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice
HEIDELBERG-ENGINEERING21.9.2018 18:43 | pressemeddelelse
Heidelberg Engineering Announces the CE-Marking of ANTERION
JEDOX21.9.2018 17:48 | pressemeddelelse
Florian Winterstein Becomes New CEO of Jedox
AVINOR21.9.2018 16:39 | pressemeddelelse
Avinor to Test Autonomous Snowploughs at Oslo Airport This Winter
MA-TAKEDA-PHARMACEUTICAL21.9.2018 15:32 | pressemeddelelse
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum